Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AFTX-201
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Affinia Therapeutics Announces BAG3 DCM Development Candidate for Pre-IND
Details : Potential best-in-class gene therapy, one-time intravenous injection, AFTX-201 (BAG3 protein levels enhancer), is being investigated for the treatment of BAG3 dilated cardiomyopathy.
Product Name : AFTX-201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : AFTX-201
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting
Details : Direct administration of AAV-based Gene Therapies to the central nervous system (CNS) can increase transduction and expression in the CNS. However, even with direct administration, vector "escapes" the CNS and distributes to peripheral organs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anc80L65
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Agreement
Details : Lonza has worked with Affinia Therapeutics to achieve a four-fold improvement in yield for the company’s lead capsid, Anc80L65. Lonza and Affinia Therapeutics are partnering with the goal of ensuring flexible manufacturing capacity for the next several...
Product Name : Anc80L65
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Anc80L65
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : EcoR1 Capital
Deal Size : $110.0 million
Deal Type : Series B Financing
Affinia Therapeutics Closes $110 Million Series B Financing
Details : Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : EcoR1 Capital
Deal Size : $110.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 27, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Vertex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Atlas Venture
Deal Size : $60.0 million
Deal Type : Series A Financing
Details : The proceeds will be used to advance the company’s platform and develop transformative gene therapies for people affected by muscle and central nervous system (CNS) diseases with significant unmet need.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 31, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Atlas Venture
Deal Size : $60.0 million
Deal Type : Series A Financing